When procuring CJC 1295 online for institutional or laboratory research, verification of chemical identity, purity, and freedom from endotoxins is critical. PX1 Research supplies high-purity CJC 1295 reagents paired with lot-specific, third-party analytical certification for rigorous in vitro and preclinical investigation.
When procuring CJC 1295 online for institutional or laboratory research, verification of chemical identity, purity, and freedom from endotoxins is critical. PX1 Research supplies high-purity CJC 1295 reagents paired with lot-specific, third-party analytical certification for rigorous in vitro and preclinical investigation.
When sourcing CJC 1295 online for laboratory research, investigators must select dedicated scientific suppliers that furnish lot-specific, third-party analytical verification. CJC-1295 is a synthetic 29-amino-acid growth hormone-releasing hormone (GHRH) analog studied in preclinical models for its ability to stimulate growth hormone (GH) secretion and sustain downstream insulin-like growth factor 1 (IGF-1) levels for tissue repair research.
To ensure experimental reproducibility and eliminate confounding variables in cell culture or animal assays, research compounds must be obtained from verified facilities. PX1 Research delivers analytical-grade reagents manufactured in the United States, fully supported by high-performance liquid chromatography (HPLC) and mass spectrometry (MS) documentation across our entire catalog of research peptides.
CJC-1295 is a modified sequence of the truncated growth hormone-releasing factor peptide, specifically GRF (1-29). The standard native GHRH peptide is rapidly degraded in biological matrices by endogenous enzymes, primarily dipeptidyl peptidase IV (DPP-IV), resulting in a biological half-life of only a few minutes. To overcome this kinetic limitation in preclinical trial design, CJC-1295 incorporates four strategic amino acid substitutions: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27.
These structural modifications stabilize the helical conformation of the peptide chain, rendering it significantly resistant to enzymatic cleavage. In laboratory models, this chemical stabilization allows researchers to observe sustained receptor activation. When evaluating CJC-1295 without DAC against versions incorporating the Drug Affinity Complex (DAC), investigators can systematically measure differences in plasma protein binding, half-life extension, and receptor interaction kinetics.
At the cellular level, CJC-1295 functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a G-protein coupled receptor located predominantly on anterior pituitary somatotrophs. Ligand binding activates the Gαs subunit, which subsequently stimulates membrane-bound adenylyl cyclase. This activation triggers an intracellular surge of cyclic adenosine monophosphate (cAMP), activating protein kinase A (PKA).
The resulting phosphorylation cascade stimulates the transcription factor CREB, upregulating growth hormone gene expression and promoting the exocytosis of stored GH granules. Preclinical studies suggest that this preserved receptor activation cascade leads to an increase in biological serum growth hormone concentrations without disrupting endogenous feedback inhibition mechanisms. Researchers exploring broader endocrine pathways can consult our comprehensive GHRH analogs research guide for extended biochemical pathways.
In vitro and animal model data indicate that sustained GHRH receptor stimulation by CJC-1295 results in continuous, extended elevation of downstream serum IGF-1 levels. Because IGF-1 serves as a principal mediator of cell proliferation, protein synthesis, and extracellular matrix remodeling, CJC-1295 is widely utilized in laboratory protocols examining tissue repair, wound healing dynamics, and musculoskeletal adaptation.
Furthermore, preclinical investigations have focused on the peptide's capacity to influence metabolic parameters, including lipolysis, nitrogen retention, and cellular energy homeostasis. By elevating systemic IGF-1 in rodent models without causing acute, destabilizing GH spikes, CJC-1295 offers a stable experimental platform for mapping cellular regeneration pathways over prolonged observation periods.
A primary distinction in research design involves choosing between CJC-1295 with DAC and CJC-1295 without DAC (often referred to as Modified GRF 1-29). The Drug Affinity Complex (DAC) is a reactive maleimido derivative covalently attached to the lysine residue at the C-terminus of the peptide. This moiety rapidly binds to bioconjugate targets—specifically circulating serum albumin—upon administration in animal models.
Binding to albumin shields the peptide from renal clearance and enzymatic breakdown, extending its biological half-life from approximately 30 minutes (without DAC) to several days (with DAC). Researchers requiring tight temporal control over GHRH exposure often prefer CJC-1295 without DAC, whereas studies evaluating long-term, basal IGF-1 elevation typically select CJC-1295 with DAC. Detailed comparative methodologies are available through the PX1 research library.
To optimize experimental design, researchers frequently compare CJC-1295 with other GH axis secretagogues. While CJC-1295 acts directly upon the GHRH receptor, complementary compounds operate through entirely distinct molecular pathways. For instance, the Ipamorelin peptide functions as a selective agonist at the growth hormone secretagogue receptor (GHSR-1a), bypassing the GHRH receptor altogether to induce pulsatile GH release.
Conversely, first-generation analogs such as the Sermorelin reference standard share the native 29-amino-acid baseline sequence of GHRH but lack the four stabilizing substitution mutations found in CJC-1295, resulting in rapid enzymatic clearance. Integrating CJC-1295 alongside ghrelin receptor agonists like Ipamorelin in preclinical models often demonstrates additive or synergistic GH release. For an in-depth breakdown of dual-receptor agonist strategies, review our dedicated resource on growth hormone secretagogues.
Acquiring research peptides online requires meticulous supplier verification to ensure data integrity and prevent experimental failure. Substandard or unverified reagents often exhibit primary sequence degradation, truncated peptide fragments, high counter-ion contamination (such as excess trifluoroacetic acid), or high endotoxin burdens that mask or distort cellular responses.
PX1 Research enforces strict quality control protocols. Every lot of CJC-1295 is manufactured in cGMP-compliant US facilities and subjected to independent, third-party testing at ISO 17025 accredited laboratories. Reagents are tested via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to guarantee purity levels exceeding 98%, and Electrospray Ionization Mass Spectrometry (ESI-MS) to verify exact molecular weight and sequence identity. Laboratories seeking volume supply agreements can establish dedicated accounts through our wholesale laboratory portal.
Bacterial endotoxins (lipopolysaccharides) represent a significant confounding variable in cell culture and animal research. Endotoxin contamination can trigger non-specific inflammatory signaling, alter cytokine release, and induce cellular toxicity, rendering assay results invalid. For high-fidelity research, peptide compounds must undergo rigorous Chromogenic Reagent or Limulus Amebocyte Lysate (LAL) testing.
PX1 Research certifies that all published lots of CJC-1295 meet strict endotoxin thresholds (typically <0.01 EU/mg). By maintaining rigorous quality assurance standards from initial synthesis to final vial sealing, we ensure that laboratory investigators receive stable, sterile, and unadulterated research compounds capable of yielding consistent experimental data.
Proper handling and reconstitution protocols are vital to preserve the structural integrity of CJC-1295 in a laboratory setting. CJC-1295 is delivered as a lyophilized (freeze-dried) powder sealed under an inert atmosphere. To reconstitute, technicians should allow the vial to equilibrate to room temperature before introducing an appropriate sterile diluent, such as Bacteriostatic Water (0.9% benzyl alcohol) or sterile laboratory-grade saline.
The diluent should be introduced slowly down the interior glass wall of the vial to minimize shear stress on the peptide matrix. The vial should be gently swirled until complete dissolution occurs; shaking or violent agitation must be avoided, as it can cause mechanical shear and peptide aggregation. Once reconstituted, stock solutions should be aliquoted using sterile technique to minimize freeze-thaw cycles during subsequent experimental procedures.
In its lyophilized form, CJC-1295 exhibits high stability when stored at micro-temperatures. For short-term storage (1–3 months), unopened lyophilized vials may be maintained at -20°C. For long-term archival storage (up to 24 months), vials should be preserved at -80°C, protected from light and moisture exposure. Reconstituted aqueous solutions remain stable at 2°C to 8°C for up to 30 days when formulated with bacteriostatic preservatives.
PX1 Research maintains cold-chain integrity across all inventory and dispatches orders rapidly from our distribution centers in California and Arizona. Orders placed Monday through Friday ship same-day, ensuring that researchers receive pristine compounds without degradation during transport. Every shipment includes comprehensive documentation linking directly to lot-specific Certificate of Analysis data.
What is CJC-1295 and what is its primary target in laboratory models?
CJC-1295 is a synthetic 29-amino-acid peptide derivative of growth hormone-releasing hormone (GHRH). It targets and selectively activates the GHRH receptor on anterior pituitary somatotrophs, stimulating growth hormone synthesis and downstream IGF-1 secretion in preclinical research.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC includes a Drug Affinity Complex that covalently binds to circulating serum albumin, extending its biological half-life to several days in animal models. CJC-1295 without DAC (Modified GRF 1-29) lacks this complex, demonstrating a shorter half-life of approximately 30 minutes, allowing for precise temporal control.
What analytical documentation is provided when buying CJC-1295 online from PX1 Research?
Every lot of CJC-1295 includes a lot-specific Certificate of Analysis (COA) generated by an independent ISO 17025 accredited laboratory. Documentation includes RP-HPLC purity profiles (>98%), Mass Spectrometry (MS) identity verification, and LAL endotoxin test results.
How should lyophilized CJC-1295 be stored in the lab?
Lyophilized CJC-1295 should be stored at -20°C for short-term projects or -80°C for long-term preservation. Storage containers should remain desiccated and protected from direct light exposure to prevent hydrolysis or photolytic degradation.
How is CJC-1295 reconstituted for laboratory assays?
Reconstitute CJC-1295 by introducing a sterile solvent (such as bacteriostatic water) along the inner glass wall of the vial. Gently swirl the container until the powder fully dissolves. Avoid vigorous shaking to prevent peptide denaturation.
What are the acceptable endotoxin levels for research-grade CJC-1295?
High-purity research compounds intended for rigorous in vitro or animal models should maintain endotoxin levels below 0.01 EU/mg to avoid confounding cellular responses or triggering non-specific immune signaling.
Can CJC-1295 be combined with other GH secretagogues in preclinical research?
Yes, preclinical studies frequently evaluate CJC-1295 alongside ghrelin mimetics such as Ipamorelin. Combining GHRH receptor agonists with GHSR agonists often produces synergistic growth hormone release in experimental models.
Where are PX1 Research CJC-1295 compounds manufactured and shipped from?
PX1 Research compounds are manufactured in cGMP-compliant facilities within the United States. Orders ship directly from our fulfillment centers in California and Arizona, with same-day shipping available for orders placed Monday through Friday.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.